Rein Therapeutics, Inc. Common Stock RNTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$5.84M-6.1% | -$31.97M+22.0% | -$5.58M+4.5% | -$6.82M+23.7% | -$5.5M+22.7% | ||
| —— | —— | —— | $1K-75.0% | $0-100% | ||
| $156K-40.9% | $257K+93.2% | $1.45M+185% | $256K-21.5% | $264K+76.0% | ||
| —— | $7.18M-22.4% | $7.18M-22.4% | $7.18M-22.4% | $7.18M-22.4% | ||
| $2.29M+861% | —— | —— | $4.88M+455% | $238K-75.4% | ||
| $247K+2,570% | —— | -$34K-108% | -$3.16M-278% | -$10K+98.7% | ||
| -$103K-182% | —— | $219K+206% | —— | $125K+168% | ||
| $0+100% | —— | —— | —— | -$277K— | ||
| —— | -$178K+54.2% | -$178K+54.2% | -$178K+54.2% | -$178K+54.2% | ||
| $623K— | —— | —— | —— | $0— | ||
| -$3.42M+44.6% | -$3.22M+33.1% | -$3.55M+7.1% | -$6.42M+23.5% | -$6.18M-17.2% | ||
| —— | —— | —— | —— | —— | ||
| $354K-52.0% | $1.45M— | —— | —— | $737K— | ||
| $4.65M+531% | $2.41M+240,400% | $1.9M— | $4.71M-74.2% | $738K— | ||
| $1.23M+123% | -$833K+82.7% | -$1.67M+60.8% | -$1.71M-117% | -$5.44M-3.1% | ||
| $623K— | —— | —— | —— | $0— | ||
| —— | $7.18M-22.4% | $7.18M-22.4% | $7.18M-22.4% | $7.18M-22.4% | ||
| $247K+2,570% | —— | -$34K-108% | -$3.16M-278% | -$10K+98.7% | ||
| $0+100% | —— | —— | —— | -$277K— | ||
| $1M+31.3% | $0— | -$2.34M-232% | $1.58M+963% | $764K+159% | ||
| -$103K-182% | —— | $219K+206% | —— | $125K+168% | ||
| —— | $0— | $0— | $0-100% | $0-100% | ||
| $4.3M— | —— | —— | —— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Rein Therapeutics, Inc. Common Stock generate?
- Rein Therapeutics, Inc. Common Stock (RNTX) generated -$16.6M in operating cash flow over the trailing twelve months.
- Where does Rein Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.